IMCCIMCCConsumer Non-Cyclicals · Drug Manufacturers - Specialty & Generic

IMCC Stock Forecast: IM Cannabis Corp. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.50

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 24 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$922,081.00
Ticker Nerd rank
24/ 100
Median analyst target
—
Analysts covering
—
Revenue$8.7M−30.6% y/y
Operating income−$1.7M
Net income−$2.5M
Free cash flow−$191K
Quarterly, 7 quarters to 31 Mar 2026 · latest quarter's figure shown
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores IM Cannabis Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
24/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
100
Issuance
55
Value
33
Revisions
20
Momentum
20
Quality
17
Volatility
11
Growth
4

Accruals (100): Reported profit is backed by cash, and the company is not expanding recklessly.

Growth (4): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

IMCC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IMCC, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
31 Dec 2021Roth CapitalInitiatesBuy—
5 Oct 2021Roth CapitalInitiatesBuy—
10 June 2021Alliance Global PartnersInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

IMCC appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Estimates

IMCC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
0.0×

Cheaper than 99% of US stocks

Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
16.3%

Higher than 16% of US stocks

Operating margin
−18.9%

Higher than 23% of US stocks

Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−19.5%

Higher than 20% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • IM Cannabis Corp. has a market value of $922K and an enterprise value of $4.4M.

  • Revenue in the twelve months to 31 Mar 2026: $50.9M. The latest quarter shrank 30.6% year on year.

  • Net income over the same four quarters: −$14.4M, a −28.3% net margin.

  • Free cash flow in the twelve months to 31 Mar 2026: $49K, after $18K of capital spending.

  • IM Cannabis Corp. spent $0.0 on dividends in the twelve months to 31 Mar 2026.

  • Shares outstanding: 614,720.

  • IM Cannabis Corp. employs 44 people — $1.2M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

IMCC and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
IMCCIM Cannabis Corp.$922,081.0024
PRFXPRF Technologies Ltd.$1.7M4
SXTCChina Sxt Pharmaceuticals, Inc.$1.8M7
SBFMSunshine Biopharma, Inc.$1.8M34
GELSGelteq Ltd.$2.9M10
APUSApimeds Pharmaceuticals US, Inc.$3.0M11
SNOASonoma Pharmaceuticals, Inc.$3.7M21

Take a look at IMCC’s peer groups, ranked by the model: consumer staples stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own IM Cannabis Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about IMCC

How does Ticker Nerd's model rank IMCC?

As at 21 Nov 2026, IM Cannabis Corp. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (100 of 100).

What is the IMCC stock forecast for 2030?

No analyst covering IM Cannabis Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMCC are extrapolating price history, which says nothing about the business.

What does IM Cannabis Corp. do?

IM Cannabis Corp. is an international medical cannabis company focused on importing, distributing, and selling cannabis-based products for medical patients in Israel and Germany. The company offers dried flower and full-spectrum cannabis extract products under brands including IMC, BLKMT, and LOT420, with a business model centered on regulated medical markets and pharmacy-based supply chains.

Company

About IM Cannabis Corp.

IM Cannabis Corp. is an international medical cannabis company focused on importing, distributing, and selling cannabis-based products for medical patients in Israel and Germany. The company offers dried flower and full-spectrum cannabis extract products under brands including IMC, BLKMT, and LOT420, with a business model centered on regulated medical markets and pharmacy-based supply chains. Its operations include product sourcing, quality control, and market-specific distribution across Europe and the Middle East, supporting physicians, pharmacies, and patients who rely on standardized cannabis formulations. IM Cannabis Corp. also maintains an online and retail presence tied to its medical cannabis ecosystem, reinforcing its role as a specialized supplier within the healthcare and life sciences sectors. Headquartered in Kibbutz Glil-Yam, Israel, the company remains positioned as a focused participant in the growing regulated medical cannabis market.

CEO Mr. Oren Shuster · 44 employees · Canada · https://imcannabis.com